8月19日(一) | 12:00 – 3:00 PM
SC1: The Making of Bispecific Antibodies
Roland E. Kontermann, PhD, Professor, Institute of Cell Biology and Immunology, Stuttgart Research Center Systems Biology, University of Stuttgart
Oliver Seifert, PhD, Senior Scientist, Institute of Cell Biology and Immunology, University of Stuttgart
The concept of using bispecific antibodies for tumor therapy has been developed more than 30 years ago, although initially with limited success. New developments in the field of antibody engineering have led to next generation bispecific antibodies and a revival of these molecules for tumor therapy. Currently, more than 100 different bispecific antibody formats have been described, including many IgG and IgG-like molecules but also a plethora of small molecules, and more than 50 bispecific antibodies are currently in clinical trials. The workshop will provide an overview of the various bispecific antibody formats and discuss the advantages and disadvantages for therapeutic applications, including dual-targeting strategies in cancer therapy and the treatment of inflammatory and infectious diseases.
8月19日(一) | 3:30 – 6:30 PM
SC2: Developability and Manufacturing Considerations for Bispecific Antibodies
Matthew Aspelund, PhD, Scientist II, Purification Process Sciences, AstraZeneca
Neil Mody, MSc, Scientist II, Early Stage Formulation Sciences, Dosage Form Design and Development (DFDD), AstraZeneca
Chunlei Wang, PhD, Senior Scientist, Analytical Sciences, AstraZeneca
Bispecific antibodies are a rapidly growing and clinically validated class of antibodies; however, multiple formats and a tedious candidate selection process such as the development of a cell line, a manufacturing process, or a formulation, are typically carried out for only one candidate and are difficult to scale up or expand to other formats/candidates. This short course focuses on challenges with discovery and development of bispecific antibodies through examining the varied aspects of developability, manufacturing, and analytical considerations to maximize the likelihood of translating a clinical candidate molecule with promising properties at an early stage of drug development into a stable, manufacturable, safe, and efficacious drug.
*Separate registration required for Short Courses.